RxDoctor Payments Data

Hasan Khan, DO

Family Medicine · Houston, TXNPI 1215270152

Payments from drug & device makers

$365in general payments, 2019–2025

Across 9 payments — averaging $40.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$173
  • Medtronic$53
  • Novartis$30
  • Pfizer$29
  • Amarin Pharma, Inc.$23
  • Exact Sciences$16
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$365 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$5,429
Medicare patients
15
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$53,029
JardianceEmpagliflozin35$39,800
FarxigaDapagliflozin Propanediol28$35,954
TradjentaLinagliptin32$30,157
JanuviaSitagliptin Phosphate23$29,695
Tresiba Flextouch U-100Insulin Degludec47$21,745
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,262
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,971
Albuterol Sulfate HfaAlbuterol Sulfate116$4,036
Atorvastatin Calcium407$3,589
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,153
Gabapentin173$2,830
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,132
Levemir FlexpenInsulin Detemir13$2,069
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic23$1,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$14$69,95767 claims
PfizerEliquis$29$53,02947 claims
MerckJanuvia$13$29,69523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →